Medicus Pharma reported audited financial results for the year ended December 31 2025, posting a net loss of $35.4 million—an increase from the $11.2 million loss reported in 2024—reflecting intensified research and development and general‑administrative spending on its SkinJect and Teverelix programs.
The company’s cash balance rose to $8.7 million from $4.2 million at the end of 2024, yet it disclosed substantial doubt about its ability to continue as a going concern without additional financing, underscoring the need for future capital injections.
Clinical milestones included the completion of a Phase 2 study of SkinJect, which achieved 73 % clinical clearance and 40 % histological clearance at Day 57 in the 200 µg cohort, and progress on Teverelix, supported by a LifeArc license amendment that reduced royalty obligations and improved the asset’s long‑term economic profile.
Strategic initiatives expanded with a collaboration with Reliant AI to deploy agentic AI‑driven clinical development tools, aiming to enhance trial efficiency and predictability; the company also highlighted its integration of AI capabilities into its development pipeline.
Management emphasized the significance of these developments, stating, "2025 marked a pivotal year for Medicus, highlighted by completion of our Phase 2 SkinJect study, efforts to expand into rare disease and women's health indications, and the integration of agentic AI‑driven clinical development capabilities." Dr. Raza Bokhari added, "The strength of our clinical dataset, combined with regulatory alignment and potential access to capital resources, positions the Company to advance toward registrational planning and strategic partnerships in 2026 and beyond."
Investor sentiment was initially buoyed by the robust SkinJect data, but concerns over the widening net loss and the going‑concern disclosure tempered overall enthusiasm.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.